Please login to the form below

Not currently logged in

Chris Bowden joins Agios

He is former VP, product development oncology at Genentech
Agios Chris Bowden

Agios Pharma has named former Genentech VP Chris Bowden as chief medical officer.

Bowden spent eight years at Genentech as VP, product development for its oncology unit. During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

Both drugs are now marketed by Roche since its takeover of Genentech in 2009.

Bowden's knowledge of oncology will benefit Agios as it prepares to advance the development of three candidates focused on cancer and inborn errors of metabolism.

“Agios is leading the investigation of precision medicine in the field of cellular metabolism, and has rapidly advanced several promising oral medicines to treat a range of serious diseases,” said Bowden.

Prior to working for Genentech Bowden spent three years as executive director for EMEA for Bristol-Myers Squibb. His earlier industry career includes spells as Janssen and Pharmacia.

15th May 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....